The metastatic triple-negative breast cancer (mTNBC) market is estimated to be valued at USD 1.57 Bn in 2024 and is expected to reach USD 2.2 Bn by 2031, growing at a compound annual growth rate (CAGR) of 5% from 2024 to 2031. https://medium.com/@siddhicmi/emerging-therapies-and-treatments-impacting-the-metastatic-triple-negative-breast-cancer-market-23ea6eedba5f